“Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Scalp, Nail, and Palmoplantar Psoriasis: Subgroup Analyses of the Phase 3 POETYK PSO-1 and PSO-2 Trials”. 2022. SKIN The Journal of Cutaneous Medicine 6 (6): s49. https://doi.org/10.25251/skin.6.supp.49.